All || Biopharma || Diagnostics and Life Science Tools || Medical Device || Healthcare IT || Healthcare Services || Exited


Fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China

IPO in May 2015 (HKSE: 1530)

AADI Bioscience

Clinical stage biopharmaceutical company developing a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin

Alpine Immune Sciences

Biotech company developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases


Clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology

Arcus Biosciences

Clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies

IPO in March 2018 (NASDAQ:RCUS)


Biotech company founded by Decheng Capital to develop a novel class of small molecules as cancer immunotherapies

ARMO Biosciences

Late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors

Acquired by Eli Lilly in May 2018

Checkmate Pharmaceuticals

Clinical stage biopharma company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies

EpimAb Biotherapeutics

Biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform

Hummingbird Bioscience

Biotech company, with facilities in Singapore and Silicon Valley, focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics


IMPACT Therapeutics

Clinical stage biopharmaceutical company focusing on discovery and development of best-in-class anti-cancer drugs targeting a poly (ADP-ribose) polymerase (PARP)

Terns Pharmaceuticals

Clinical stage biopharma company based in Shanghai and Silicon Valley developing oral, small molecule drugs for nonalcoholic steatohepatitis (NASH), a liver disease



Biopharma company focused on developing an antibody-drug conjugate of cirmtuzumab, a ROR1 antibody

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.